Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 4 1Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 24Neoplasms 11Carcinoma, Non-Small-Cell Lung 9Prostatic Neoplasms 8Multiple Myeloma 8Lung Neoplasms 6Melanoma 5Leukemia, Myeloid, Acute 5Neoplasm Metastasis 4Glioma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Tuberous Sclerosis 3Stomach Neoplasms 3Sarcoma 3Papillomavirus Infections 3Leiomyoma 3Hematologic Neoplasms 3Glioblastoma 3Carcinoma, Renal Cell 3Polycythemia Vera 2Pain 2Oligodendroglioma 2Neoplasms by Site 2Myasthenia Gravis 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Heart Failure 2Febrile Neutropenia 2Endometrial Neoplasms 2Bronchiolitis Obliterans Syndrome 2

Interventions

obinutuzumab 1acalabrutinib 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lymphatic Diseases × 90 days × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡